Open AccessHepatitis B virus reactivation with rituximab-containing regimen
Author(s) -
Yutaka Tsutsumi,
Yoshiya Yamamoto,
Joji Shimono,
Hiroyuki Ohhigashi,
Takanori Teshima
Publication year - 2013
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v5.i11.612
Subject(s) - medicine , rituximab , thrombocytopenic purpura , rheumatoid arthritis , immunology , regimen , lymphoma , thrombotic thrombocytopenic purpura , hepatitis b , virology , immune system , platelet
Rituximab is recognized as a useful drug for the treatment of B-cell non-Hodgkin's lymphoma and its use has been extended to such diseases as idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, chronic rheumatoid arthritis and ANCA-associated vasculitides. One serious complication associated with its use is the reactivation of hepatitis B virus and the search for methods to prevent this occurrence has resulted in the rapid accumulation of knowledge. In this review, we discuss case analyses from our department and other groups and outline the current knowledge on the topic and the remaining issues.